Skip to main content

Master of Public Health

Agreement Between Two Procalcitonin Assays in Hospitalized Children

AUTHORS

Katz SE , Sartori LF , Szeles A , McHenry R , Stanford JE , Xu M , Colby JM , Halasa N , Williams DJ , Banerjee R , . Infectious diseases and therapy. 2019 6 29; ().

ABSTRACT

INTRODUCTION: Agreement between available procalcitonin (PCT) assays is unclear. We sought to compare concordance between Roche and bioMérieux PCT assays using pediatric samples.

METHODS: We evaluated 213 plasma samples from 208 children. We tested each sample on both the Roche and bioMérieux PCT platforms.

RESULTS: At ranges < 2 μg/L, the Roche platform had a mean negative bias of 0.13 μg/L versus the bioMérieux platform. This bias resulted in PCT levels that crossed accepted cut points in 12.7% of patients.

CONCLUSIONS: PCT levels measured on either platform are similar, especially at PCT ranges used for antibiotic decision-making algorithms.

FUNDING: This work was supported by an investigator-initiated research agreement through bioMérieux and by the National Institute of Allergy and Infectious Diseases Childhood Infection Research Program (ChIRP), National Institute of Health and the National Center for Advancing Translational Sciences of the National Institute of Health.

Tags: ,